Notes
The study was affiliated with, and funded by, Apellis Pharmaceuticals.
Reference
Cheng WY, et al. Real-World Healthcare Resource Utilization (HRU) and Costs of Patients with Paroxysmal Nocturnal Hemoglobinuria (PNH) Receiving Eculizumab in a US Population. Advances in Therapy : 17 Jul 2021. Available from: URL: http://doi.org/10.1007/s12325-021-01825-4
Rights and permissions
About this article
Cite this article
Costs higher for PNH patients receiving eculizumab plus blood transfusions in the USA. PharmacoEcon Outcomes News 884, 8 (2021). https://doi.org/10.1007/s40274-021-7915-5
Published:
Issue Date:
DOI: https://doi.org/10.1007/s40274-021-7915-5